Skip to main content
SpringerLink
Log in

Spatiotemporal Changes in Checkpoint Molecule Expression

  • Chapter
  • First Online:
Regulation of Cancer Immune Checkpoints

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1248))

Abstract

Immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 blockade, have led to therapeutic breakthrough in patients with advanced malignancy, covering the lung, breast, gastrointestinal, head and neck, urinary system, lymphoma, and solid tumor harboring MSI/dMMR. In certain cancer types, the expression level of immune checkpoint molecule will be required if the immune-based approaches are considered, especially the PD-L1 expression. However, in other types, survival benefit has been proven regardless of PD-L1 expression. It raises a question of how to select patients for immune therapy and whether the expression of immune checkpoint molecules will be optimal biomarkers. Before answering this question, a comprehensive map for the expression of immune checkpoint molecules is needed. In this chapter, we describe our current knowledge on the spatiotemporal changes in the expression of checkpoint molecules. We discuss the different frequencies of expression depending on tumor types and stages, the different patterns between primary and metastatic tumors, as well as the change of expression before and after treatment. The expression of PD-L1 has been most studied, but the threshold that separate “positive” and “negative” PD-L1 expressions and the consistency of testing platform remain under debate. Better understanding on the tumor microenvironment and expression of checkpoint molecules will help to identify patients who will benefit from checkpoint blockade therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ali HR, Glont SE, Blows FM et al (2015) PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol: Off J Eur Soc Med Oncol 26(7):1488–1493

    Article  CAS  Google Scholar 

  • Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372(4):311–319

    Article  CAS  PubMed  Google Scholar 

  • Antonia SJ, López-Martin JA, Bendell J et al (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17(7):883–895

    Article  CAS  PubMed  Google Scholar 

  • Arigami T, Narita N, Mizuno R et al (2010) B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 252(6):1044–1051

    Article  PubMed  Google Scholar 

  • Balar AV, Castellano D, O’Donnell PH et al (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(11):1483–1492

    Article  CAS  PubMed  Google Scholar 

  • Baptista MZ, Sarian LO, Derchain SF, Pinto GA, Vassallo J (2016) Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol 47(1):78–84

    Article  CAS  PubMed  Google Scholar 

  • Baruah P, Bullenkamp J, Wilson POG, Lee M, Kaski JC, Dumitriu IE (2019) TLR9 mediated tumor-stroma interactions in Human Papilloma Virus (HPV)-positive head and neck squamous Cell carcinoma Up-regulate PD-L1 and PD-L2. Front Immunol 10:1644

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bauml J, Seiwert TY, Pfister DG et al (2016) Preliminary results from KEYNOTE-055: pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 34(15_suppl):6011

    Google Scholar 

  • Bedekovics J, Beke L, Mokanszki A, Szilagyi S, Mehes G (2018) Programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors. Appl Immunohistochem Mol Morphol

    Google Scholar 

  • Bellmunt J, Mullane SA, Werner L et al (2015) Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 26(4):812–817

    Article  CAS  PubMed  Google Scholar 

  • Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bin Z, Guangbo Z, Yan G, Huan Z, Desheng L, Xueguang Z (2014) Overexpression of B7-H3 in CD133 + colorectal cancer cells is associated with cancer progression and survival in human patients. J Surg Res 188(2):396–403

    Article  CAS  PubMed  Google Scholar 

  • Boger C, Behrens HM, Kruger S, Rocken C (2017) The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy? Oncoimmunology 6(4):e1293215

    Article  PubMed  PubMed Central  Google Scholar 

  • Boorjian SA, Sheinin Y, Crispen PL et al (2008) T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 14(15):4800–4808

    Article  CAS  PubMed  Google Scholar 

  • Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brown H, Vansteenkiste J, Nakagawa K et al (2019) Brief report: programmed cell death ligand 1 expression in untreated EGFR mutated advanced non-small cell lung cancer and response to osimertinib versus comparator in FLAURA. J Thorac Oncol

    Google Scholar 

  • Burugu S, Gao D, Leung S, Chia SK, Nielsen TO (2018) TIM-3 expression in breast cancer. Oncoimmunology 7(11):e1502128

    Article  PubMed  PubMed Central  Google Scholar 

  • Callea M, Albiges L, Gupta M et al (2015) Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res 3(10):1158–1164

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Camisaschi C, De Filippo A, Beretta V et al (2014) Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Invest Dermatol 134(7):1893–1902

    Article  CAS  PubMed  Google Scholar 

  • Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202-209

    Google Scholar 

  • Cappello P, Triebel F, Iezzi M et al (2003) LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Can Res 63(10):2518–2525

    CAS  Google Scholar 

  • Carbone DP, Reck M, Paz-Ares L et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376(25):2415–2426

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen BJ, Chapuy B, Ouyang J et al (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res: Off J Am Assoc Cancer Res 19(13):3462–3473

    Article  CAS  Google Scholar 

  • Cheng G, Li M, Wu J et al (2015) Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis. Int J Clin Exp Pathol 8(8):9452–9457

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chung HC, Ros W, Delord JP et al (2019) Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol: Off J Am Soc Clin Oncol 37(17):1470–1478

    Article  CAS  Google Scholar 

  • Cong F, Yu H, Gao X (2017) Expression of CD24 and B7-H3 in breast cancer and the clinical significance. Oncol Lett 14(6):7185–7190

    PubMed  PubMed Central  Google Scholar 

  • Cooper WA, Tran T, Vilain RE et al (2015) PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 89(2):181–188

    Article  PubMed  Google Scholar 

  • D’Angelo SP, Shoushtari AN, Agaram NP et al (2015) Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 46(3):357–365

    Article  CAS  PubMed  Google Scholar 

  • Dail M, Yang L, Green C et al (2016) Distinct patterns of PD-L1 and PD-L2 expression by tumor and non-tumor cells in patients with MM, MDS and AML. Blood 128(22):1340

    Google Scholar 

  • Danilova L, Wang H, Sunshine J et al (2016) Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci USA 113(48):E7769–E7777

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Das S, Suarez G, Beswick EJ, Sierra JC, Graham DY, Reyes VE (1950) Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol (Baltimore, Md: 1950) 176(5):3000–3009

    Google Scholar 

  • Deng L, Gyorffy B, Na F et al (2015) Association of PDCD1 and CTLA-4 gene expression with clinicopathological factors and survival in non-small-cell lung cancer: results from a large and pooled microarray database. J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer 10(7):1020–1026

    Article  CAS  Google Scholar 

  • Derks S, Nason KS, Liao X et al (2015) Epithelial PD-L2 expression marks Barrett’s esophagus and esophageal adenocarcinoma. Cancer Immunol Res 3(10):1123–1129

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dietel M, Savelov N, Salanova R et al (2018) 130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): the global, multicentre EXPRESS study. J Thorac Oncol 13(4):S74–S75

    Article  Google Scholar 

  • Dill EA, Gru AA, Atkins KA et al (2017) PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors. Am J Surg Pathol 41(3):334–342

    Article  PubMed  Google Scholar 

  • Doi T, Piha-Paul SA, Jalal SI et al (2018) Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 36(1):61–67

    Google Scholar 

  • Doroshow DB, Sanmamed MF, Hastings K et al (2019) Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res: Off J Am Assoc Cancer Res

    Google Scholar 

  • Droeser RA, Hirt C, Viehl CT et al (2013) Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49(9):2233–2242

    Article  CAS  PubMed  Google Scholar 

  • El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet (London, England) 389(10088):2492–2502

    Article  CAS  Google Scholar 

  • Emens LA, Cruz C, Eder JP et al (2019) Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 studyatezolizumab therapy for patients with metastatic triple-negative breast canceratezolizumab therapy for patients with metastatic triple-negative breast cancer. JAMA Oncol 5(1):74–82

    Article  PubMed  Google Scholar 

  • Enwere EK, Kornaga EN, Dean M et al (2017) Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol: Off J U S Can Acad Pathol, Inc 30(4):577–586

    Google Scholar 

  • Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Frenel JS, Le Tourneau C, O’Neil B et al (2017) Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol: Off J Am Soc Clin Oncol 35(36):4035–4041

    Article  CAS  Google Scholar 

  • Fuchs CS, Doi T, Jang RW et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4(5):e180013

    Article  PubMed  PubMed Central  Google Scholar 

  • Fujimoto D, Uehara K, Sato Y et al (2017) Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep 7(1):11373

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gandhi MK, Lambley E, Duraiswamy J et al (2006) Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8 + T-cell function in Hodgkin lymphoma patients. Blood 108(7):2280–2289

    Article  CAS  PubMed  Google Scholar 

  • Gao Q, Wang XY, Qiu SJ et al (2009) Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res 15(3):971–979

    Article  CAS  Google Scholar 

  • Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 372(21):2018–2028

    Article  PubMed  Google Scholar 

  • Gettinger SN, Horn L, Gandhi L et al (2015) Overall survival and long-term safety of nivolumab (Anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously Treated advanced non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol 33(18):2004–2012

    Article  CAS  Google Scholar 

  • Giaccone G, Kim C, Thompson J et al (2018) Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 19(3):347–355

    Article  CAS  PubMed  Google Scholar 

  • Grosso JF, Kelleher CC, Harris TJ et al (2007) LAG-3 regulates CD8 + T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Investig 117(11):3383–3392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Guo PD, Sun ZW, Lai HJ et al (2018) Clinicopathological analysis of PD-L2 expression in colorectal cancer. OncoTargets Ther 11:7635–7642

    Article  CAS  Google Scholar 

  • Hamanishi J, Mandai M, Iwasaki M et al (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104(9):3360–3365

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hamid O, Puzanov I, Dummer R et al (2017) Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer 86:37–45

    Article  CAS  PubMed  Google Scholar 

  • Han L, Liu F, Li R et al (2014) Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. Oncol Lett 8(4):1461–1469

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Han JJ, Kim DW, Koh J et al (2016) Change in PD-L1 expression after acquiring resistance to gefitinib in EGFR-mutant non-small-cell lung cancer. Clin Lung Cancer 17(4):263–270 e2

    Google Scholar 

  • Haratake N, Toyokawa G, Tagawa T et al (2017) Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab. Anticancer Res 37(10):5713–5717

    CAS  PubMed  Google Scholar 

  • Hashizume A, Umemoto S, Yokose T et al (2018) Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus calmette-guerin. Oncotarget 9(75):34066–34078

    Article  PubMed  PubMed Central  Google Scholar 

  • He Y, Yu H, Rozeboom L et al (2017) LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes. J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer 12(5):814–823

    Article  Google Scholar 

  • Heeren AM, van Dijk I, Berry D et al (2018) Indoleamine 2,3-dioxygenase expression pattern in the tumor microenvironment predicts clinical outcome in early stage cervical cancer. Front Immunol 9:1598

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England) 387(10027):1540–1550

    Article  CAS  Google Scholar 

  • Herbst RS, Baas P, Perez-Gracia JL et al (2019) Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Ann Oncol: Off J Eur Soc Med Oncol 30(2):281–289

    Article  CAS  Google Scholar 

  • Hersom M, Jorgensen JT (2018) Companion and complementary diagnostics-focus on PD-L1 expression assays for PD-1/PD-L1 checkpoint inhibitors in non-small cell lung cancer. Ther Drug Monit 40(1):9–16

    CAS  PubMed  Google Scholar 

  • Horn L, Mansfield AS, Szczesna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220–2229

    Article  CAS  PubMed  Google Scholar 

  • Hsieh C-C, Hsu H-S, Li AF-Y, Chen Y-J (2018) Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. J Thorac Dis 10(7):4433–4444

    Google Scholar 

  • Hu Y, Lv X, Wu Y et al (2015) Expression of costimulatory molecule B7-H3 and its prognostic implications in human acute leukemia. Hematology (Amsterdam, Netherlands) 20(4):187–195

    Google Scholar 

  • Ilie M, Long-Mira E, Bence C et al (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol: Off J Eur Soc Med Oncol 27(1):147–153

    Article  CAS  Google Scholar 

  • Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O (2012) B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer 131(11):2528–2536

    Article  CAS  PubMed  Google Scholar 

  • Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad O (2014) B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer 14:602

    Article  PubMed  PubMed Central  Google Scholar 

  • Inoue Y, Yoshimura K, Kurabe N et al (2017) Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget 8(5):8738–8751

    Article  PubMed  PubMed Central  Google Scholar 

  • Ise W, Kohyama M, Nutsch KM et al (2010) CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 11(2):129–135

    Article  CAS  PubMed  Google Scholar 

  • Ishii H, Azuma K, Kawahara A et al (2015) Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer 10(3):426–430

    Article  CAS  Google Scholar 

  • Janjigian YY, Bendell J, Calvo E et al (2018) CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol: Off J Am Soc Clin Oncol 36(28):2836–2844

    Article  CAS  Google Scholar 

  • Jia Y, Wang H, Wang Y et al (2015) Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J Cancer 137(5):1095–1106

    Article  CAS  PubMed  Google Scholar 

  • Jung HI, Jeong D, Ji S et al (2017) Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat: Off J Korean Cancer Assoc 49(1):246–254

    Article  CAS  Google Scholar 

  • Kakavand H, Jackett LA, Menzies AM et al (2017) Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol: Off J U S Can Acad Pathol, Inc 30(12):1666–1676

    Google Scholar 

  • Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 390(10111):2461–2471

    Article  CAS  Google Scholar 

  • Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K (2015) Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer 88(2):154–159

    Article  PubMed  Google Scholar 

  • Katsuya Y, Horinouchi H, Asao T et al (2016) Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer 99:4–10

    Article  PubMed  Google Scholar 

  • Kaufman KA, Bowen JA, Tsai AF, Bluestone JA, Hunt JS, Ober C (1999) The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod 5(1):84–87

    Article  CAS  PubMed  Google Scholar 

  • Kawazoe A, Kuwata T, Kuboki Y et al (2017) Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer: Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc 20(3):407–415

    Article  CAS  Google Scholar 

  • Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 26:677–704

    Article  CAS  Google Scholar 

  • Kim SS, Kim SH, Kang HS et al (2010) Molecular cloning and expression analysis of pig lymphocyte activation gene-3 (LAG-3; CD223). Vet Immunol Immunopathol 133(1):72–79

    Article  CAS  PubMed  Google Scholar 

  • Kim JR, Moon YJ, Kwon KS et al (2013) Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS ONE 8(12):e82870

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim S, Koh J, Kwon D et al (2017) Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. Eur J Cancer 75:141–149

    Article  CAS  PubMed  Google Scholar 

  • Kitazono S, Fujiwara Y, Tsuta K et al (2015) Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non–small-cell lung cancer. Clin Lung Cancer 16(5):385–390

    Article  CAS  PubMed  Google Scholar 

  • Kotaskova J, Tichy B, Trbusek M et al (2010) High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. J Mol Diagn: JMD 12(3):328–334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kudo T, Hamamoto Y, Kato K et al (2017) Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol 18(5):631–639

    Article  CAS  PubMed  Google Scholar 

  • Kulangara KHD, Waldroup S et al (2017) Development of the combined positive score for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx. J Clin Oncol 35S:ASCO#e14589

    Google Scholar 

  • Latchman Y, Wood CR, Chernova T et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261–268

    Article  CAS  PubMed  Google Scholar 

  • Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee LH, Cavalcanti MS, Segal NH et al (2016) Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol 29:1433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee J, Park CK, Yoon HK et al (2019) PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1. Thoracic cancer 10(1):103–110

    Article  CAS  PubMed  Google Scholar 

  • Li F, Zhao Y, Wei L, Li S, Liu J (2018) Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol Ther 19(8):695–705

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liao H, Chen W, Dai Y et al (2019) Expression of programmed cell death-ligands in hepatocellular carcinoma: correlation with immune microenvironment and survival outcomes. Front Oncol 9:883

    Article  PubMed  PubMed Central  Google Scholar 

  • Llosa NJ, Cruise M, Tam A et al (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5(1):43–51

    Article  CAS  PubMed  Google Scholar 

  • Lou Y, Diao L, Cuentas ER et al (2016) Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res 22(14):3630–3642

    Article  CAS  Google Scholar 

  • Ma W, Duan H, Zhang R et al (2019) High expression of indoleamine 2, 3-dioxygenase in adenosquamous lung carcinoma correlates with favorable patient outcome. J Cancer 10(1):267–276

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Madore J, Vilain RE, Menzies AM et al (2015) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28(3):245–253

    Article  CAS  PubMed  Google Scholar 

  • Manson QF, Schrijver W, Ter Hoeve ND, Moelans CB, van Diest PJ (2019) Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases. Clin Exp Metas 36(1):29–37

    Article  CAS  Google Scholar 

  • Masugi Y, Nishihara R, Yang J et al (2017) Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 66(8):1463–1473

    Article  CAS  PubMed  Google Scholar 

  • Mehra R, Seiwert TY, Gupta S et al (2018) Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer 119(2):153–159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mezache L, Paniccia B, Nyinawabera A, Nuovo GJ (2015) Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol: Off J U S Can Acad Pathol, Inc 28(12):1594–1602

    Google Scholar 

  • Mittendorf EA, Philips AV, Meric-Bernstam F et al (2014) PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361–370

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Motzer RJ, Rini BI, McDermott DF et al (2015a) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol: Off J Am Soc Clin Oncol 33(13):1430–1437

    Article  CAS  Google Scholar 

  • Motzer RJ, Escudier B, McDermott DF et al (2015b) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Muro K, Chung HC, Shankaran V et al (2016) Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 17(6):717–726

    Article  CAS  PubMed  Google Scholar 

  • Nagaraju K, Raben N, Villalba ML et al (1999) Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol (Orlando, Fla) 92(2):161–169

    Article  CAS  Google Scholar 

  • Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S (2007) Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol, Immunother: CII 56(8):1173–1182

    Article  CAS  PubMed  Google Scholar 

  • Nomi T, Sho M, Akahori T et al (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 13(7):2151–2157

    Article  CAS  Google Scholar 

  • Obeid JM, Erdag G, Smolkin ME et al (2016) PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunology 5(11):e1235107

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ogawa M, Watanabe M, Hasegawa T, Ichihara K, Yoshida K, Yanaga K (2017) Expression of CXCR-4 and IDO in human colorectal cancer: an immunohistochemical approach. Mol Clin Oncol 6(5):701–704

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21(1):24–33

    Article  CAS  PubMed  Google Scholar 

  • O’Malley D, Sudarsanam S, Chizhevsky V et al (2017) BRAF mutation and PD-L1 expression in melanoma: Comparison between multiple PD-L1 IHC clones and BRAF mutation evalutated by FDA-approved kits versus NGS. J Clin Oncol 35(15_suppl):e21050-e

    Google Scholar 

  • Ott PA, Fernandez MEE, Hiret S et al (2015) Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol 33(15_suppl):7502

    Google Scholar 

  • Overman MJ, McDermott R, Leach JL et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182–1191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Overman MJ, Lonardi S, Wong KYM et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol: Off J Am Soc Clin Oncol 36(8):773–779

    Article  CAS  Google Scholar 

  • Panjwani PK, Charu V, DeLisser M, Molina-Kirsch H, Natkunam Y, Zhao S (2018) Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol 71:91–99

    Article  CAS  PubMed  Google Scholar 

  • Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Paulsen EE, Kilvaer TK, Rakaee M et al (2017) CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunol, Immunother: CII 66(11):1449–1461

    Article  CAS  PubMed  Google Scholar 

  • Petrylak DP, Powles T, Bellmunt J et al (2018) Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 study. JAMA Oncol 4(4):537–544

    Article  PubMed  PubMed Central  Google Scholar 

  • Pinato DJ, Shiner RJ, White SD et al (2016) Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy. Oncoimmunology 5(9):e1213934

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833

    Article  CAS  PubMed  Google Scholar 

  • Rehman JA, Han G, Carvajal-Hausdorf DE et al (2017) Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Mod Pathol: Off J U S Can Acad Pathol, Inc 30(3):340–349

    Google Scholar 

  • Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908–918

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rijnders M, van der Veldt AAM, Zuiverloon TCM et al (2019) PD-L1 antibody comparison in urothelial carcinoma. Eur Urol 75(3):538–540

    Article  CAS  PubMed  Google Scholar 

  • Rizvi NA, Mazieres J, Planchard D et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16(3):257–265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330

    Article  CAS  PubMed  Google Scholar 

  • Rodić N, Anders RA, Eshleman JR et al (2015) PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Cancer Immunol Res 3(2):110–115

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England) 387(10031):1909–1920

    Article  CAS  Google Scholar 

  • Schachter J, Ribas A, Long GV et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet (London, England) 390(10105):1853–1862

    Article  CAS  Google Scholar 

  • Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108–2121

    Article  CAS  PubMed  Google Scholar 

  • Schultheis AM, Scheel AH, Ozretic L et al (2015) PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 51(3):421–426

    Article  CAS  PubMed  Google Scholar 

  • Sequist LV, Chiang A, Gilbert J et al (2016) Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC). Ann Oncol 27(suppl_6)

    Google Scholar 

  • Shah MA, Kojima T, Hochhauser D et al (2018) Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol

    Google Scholar 

  • Sharma P, Callahan MK, Bono P et al (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17(11):1590–1598

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shin SJ, Jeon YK, Kim PJ et al (2016) Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status. Ann Surg Oncol 23(2):694–702

    Article  PubMed  Google Scholar 

  • Silva R, Gullo I, Carneiro F (2016) The PD-1:PD-L1 immune inhibitory checkpoint in Helicobacter pylori infection and gastric cancer: a comprehensive review and future perspectives. Porto Biomed J 1(1):4–11

    Article  PubMed  PubMed Central  Google Scholar 

  • Snyder A, Makarov V, Merghoub T et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189–2199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Spira AI, Park K, Mazières J et al (2015) Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A versus docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol 33(15_suppl):8010

    Google Scholar 

  • Sun J, Xu K, Wu C et al (2007) PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens 69(1):19–27

    Article  CAS  PubMed  Google Scholar 

  • Takaya S, Saito H, Ikeguchi M (2015) Upregulation of immune checkpoint molecules, PD-1 and LAG-3, on CD4 + and CD8 + T cells after gastric cancer surgery. Yonago Acta Med 58(1):39–44

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tanaka K, Miyata H, Sugimura K et al (2016) Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Sci 107(6):726–733

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tanaka Y, Maeshima AM, Nomoto J et al (2018) Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. Eur J Haematol 100(5):511–517

    Article  CAS  PubMed  Google Scholar 

  • Tanegashima T, Togashi Y, Azuma K et al (2019) Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity. Clin Cancer Res: Off J Am Assoc Cancer Res 2019

    Google Scholar 

  • Taube JM, Anders RA, Young GD et al (2012) Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4(127):127ra37-12ra37

    Google Scholar 

  • Tessier-Cloutier B, Kalloger SE, Al-Kandari M et al (2017) Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer 17(1):618

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Thiem A, Hesbacher S, Kneitz H et al (2019) IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res 38(1):397

    Article  PubMed  PubMed Central  Google Scholar 

  • Thompson RH, Kuntz SM, Leibovich BC et al (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Can Res 66(7):3381–3385

    Article  CAS  Google Scholar 

  • Triebel F, Jitsukawa S, Baixeras E et al (1990) LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 171(5):1393–1405

    Article  CAS  PubMed  Google Scholar 

  • Vilain RE, Menzies AM, Wilmott JS et al (2017) Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin Cancer Res: Off J Am Assoc Cancer Res 23(17):5024–5033

    Article  CAS  Google Scholar 

  • Villarroel-Espindola F, Yu X, Datar I et al (2018) Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 24(7):1562–1573

    Article  CAS  Google Scholar 

  • Wainwright DA, Balyasnikova IV, Chang AL et al (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res: Off J Am Assoc Cancer Res 18(22):6110–6121

    Article  CAS  Google Scholar 

  • Wang XB, Giscombe R, Yan Z, Heiden T, Xu D, Lefvert AK (2002) Expression of CTLA-4 by human monocytes. Scand J Immunol 55(1):53–60

    Article  CAS  PubMed  Google Scholar 

  • Wang J, Chong KK, Nakamura Y et al (2013) B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol 133(8):2050–2058

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang K, Yuen ST, Xu J et al (2014) Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 46(6):573–582

    Article  CAS  PubMed  Google Scholar 

  • Wang HB, Yao H, Li CS et al (2017a) Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy. J Dig Dis 18(10):574–581

    Article  CAS  PubMed  Google Scholar 

  • Wang H, Yao H, Li C et al (2017) PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation. Oncoimmunology 6(7):e1327494-e

    Google Scholar 

  • Wang Y, Dong T, Xuan Q, Zhao H, Qin L, Zhang Q (2018) Lymphocyte-activation gene-3 expression and prognostic value in neoadjuvant-treated triple-negative breast cancer. J Breast Cancer 21(2):124–133

    Article  PubMed  PubMed Central  Google Scholar 

  • Wang X, Zhang T, Song Z et al (2019) Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome. Int J Cancer

    Google Scholar 

  • Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384

    Article  CAS  PubMed  Google Scholar 

  • Weissferdt A, Fujimoto J, Kalhor N et al (2017) Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol: Off J U S Can Acad Pathol, Inc 30(6):826–833

    Google Scholar 

  • Wimberly H, Brown JR, Schalper K et al (2015) PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 3(4):326–332

    Article  CAS  PubMed  Google Scholar 

  • Workman CJ, Wang Y, El Kasmi KC et al (2009) LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol (Baltimore, Md: 1950) 182(4):1885–1891

    Google Scholar 

  • Wu C, Zhu Y, Jiang J, Zhao J, Zhang X-G, Xu N (2006) Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108(1):19–24

    Article  PubMed  Google Scholar 

  • Xing X, Guo J, Wen X et al (2018) Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology 7(3):e1356144

    Article  PubMed  Google Scholar 

  • Yang W, Song Y, Lu Y-L, Sun J-Z, Wang H-W (2013) Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology 139(4):513–522

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yang CY, Lin MW, Chang YL, Wu CT, Yang PC (2014) Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 50(7):1361–1369

    Article  CAS  PubMed  Google Scholar 

  • Yang CY, Lin MW, Chang YL, Wu CT, Yang PC (2016) Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur J Cancer 57:91–103

    Article  CAS  PubMed  Google Scholar 

  • Yearley JH, Gibson C, Yu N et al (2017) PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 23(12):3158–3167

    Article  CAS  PubMed  Google Scholar 

  • Yu H, Yang J, Jiao S, Li Y, Zhang W, Wang J (2015) Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. Cancer Immunol, Immunother: CII 64(7):853–860

    Article  CAS  PubMed  Google Scholar 

  • Zang X, Thompson RH, Al-Ahmadie HA et al (2007) B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 104(49):19458–19463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zeng Y, Wang CL, Xian J et al (2019) Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer. Onco Targets Ther 12:7193–7201

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhang T, Tan XL, Xu Y, Wang ZZ, Xiao CH, Liu R (2017) Expression and prognostic value of indoleamine 2,3-dioxygenase in pancreatic cancer. Chin Med J 130(6):710–716

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhang Y, Liu YD, Luo YL et al (2018) prognostic value of lymphocyte activation gene-3 (LAG-3) expression in esophageal squamous cell carcinoma. J Cancer 9(22):4287–4293

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhao X, Kallakury B, Chahine JJ et al (2019) Surgical resection of SCLC: prognostic factors and the tumor microenvironment. J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer 14(5):914–923

    Article  CAS  Google Scholar 

  • Zhu AX, Finn RS, Edeline J et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19(7):940–952

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China

    Wenhua Li, Yao Zhang & Jinjia Chang

  2. Institutes of Biomedical Sciences, Fudan University, 130 Dongan Road, Shanghai, 200032, China

    Jingbo Qie

Authors
  1. Wenhua Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jingbo Qie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jinjia Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wenhua Li .

Editor information

Editors and Affiliations

  1. Institutes of Biomedical Sciences, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

    Jie Xu

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Li, W., Qie, J., Zhang, Y., Chang, J. (2020). Spatiotemporal Changes in Checkpoint Molecule Expression. In: Xu, J. (eds) Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, vol 1248. Springer, Singapore. https://doi.org/10.1007/978-981-15-3266-5_8

Download citation

Publish with us

Policies and ethics

Search

Navigation